This hypothesis is strongly supported by a retrospective clinical study of 742 ER+ low-risk (lymph node-negative, postmenopausal) breast cancer patients whose primary tumors were GPER-negative and showed improved disease-free survival [57]. This evidence concerns the gene ESR1 and breast cancer.